trending Market Intelligence /marketintelligence/en/news-insights/trending/Q1vL_06VMT2esKHwPWyWEA2 content esgSubNav
In This List

Novo Nordisk resubmits US FDA application for fast-acting insulin aspart

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Novo Nordisk resubmits US FDA application for fast-acting insulin aspart

Novo Nordisk A/S resubmitted to the U.S. FDA the new drug application for its fast-acting insulin aspart.

The treatment is intended to control postprandial glucose excursions in patients with type 1 and type 2 diabetes.

The FDA requested additional information from Novo Nordisk regarding the treatment in October 2016. The Denmark-based drugmaker has complied with the FDA's request and expects to receive feedback from the agency in the last quarter of 2017.

Fast-acting insulin aspart received marketing authorization from the European Commission on Jan. 9 and is under regulatory review in Switzerland, Australia, Brazil, South Africa, Argentina and Israel.